LONDON - EMV Capital plc (AIM:EMVC), a venture capital investment group specializing in deeptech and life sciences, has announced the grant of 345,000 new options for ordinary shares to its directors and a person discharging managerial responsibilities (PDMR). The options are part of the company's remuneration policy and align with the EMV Capital Share Option Scheme.
The scheme has now granted options over a total of 2,417,732 ordinary shares, which is approximately 8.71% of the company's issued share capital. This remains within the 10% dilution limit set by the scheme's rules. The exercise price for the new options is set at 50 pence per share. This price matches the issue price of the company's recent share issuance on December 5, 2024, and exceeds the average closing market quotations for the five days preceding the grant.
The options will vest in thirds: one-third on the date of grant, another third on the first anniversary, and the final third on the second anniversary. They are not exercisable before the third anniversary of the grant and will lapse ten years after the grant date if not exercised sooner.
The recipients of the new options include Dr. Ilian Iliev, CEO, and Ed Hooper, Executive Director, who both received 120,000 options, increasing their total holdings to 685,656 options each. Dr. Charles Spicer, Chair, and Dr. Jonathan Robinson, Senior Independent (LON:IOG) Director, were each granted 30,000 new options. Nick Salisbury, a PDMR, was awarded 45,000 options, which constitutes his total holdings.
This announcement has been made in accordance with the EU Market Abuse Regulation and is considered inside information. As such, upon its release, this information is now deemed to be in the public domain.
The information in this article is based on a press release statement from EMV Capital plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.